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ABSTRACT
Tapering Buprenorphine
Alexis Diane Snyder
College of Nursing, BYU
Master of Science
Opioid use disorder (OUD) is increasing in incidence in the United States. Buprenorphine
is the mainstay of medication-assisted treatment for OUD. Nurse practitioners play an essential
role in solving the opioid epidemic and are increasingly relied on to prescribe buprenorphine.
Even though buprenorphine is considered a long-term therapy, many patients request to taper off
the drug. Evidence suggests that tapering from buprenorphine is frequently unsuccessful and
remains as a challenge. The purpose of this article is to provide the best available evidence
regarding the taper of buprenorphine in patients with OUD. Considering a buprenorphine taper
should begin by evaluating if the patient is a good candidate, specifically if their maintenance
dose of buprenorphine is less than 8 mg/day. This evaluation should also include assessment of
the patient’s withdrawal expectation. Evidence suggests that a longer buprenorphine taper
duration combined with naltrexone leads to better results compared to shorter tapers without
naltrexone. Ancillary medications and counseling should be made available to patients as a
component of the tapering protocol. Tapering from buprenorphine is difficult but following
current evidence gives patients the best likelihood of success.
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Tapering Buprenorphine
Opioid Use Disorder (OUD) is an epidemic, affecting every state in the United States
(U.S.). The opioid epidemic is primarily due to the over-prescription of opioids for chronic pain
(National Institute on Drug Abuse, 2020). Recent evidence is now challenging the long-term use
of opioids. Despite this evidence, many patients are still dependent on opioids to manage longterm pain. Over 21% of patients taking opioids long-term will end up misusing the medications
(National Institute on Drug Abuse, 2020). This misuse often leads to OUD with or without the
introduction of heroin. Overdose deaths from illicit opioid use sharply increased 38.4% in the
first half of 2020 (Centers for Disease Control and Prevention, 2020). The effects of the opioid
crisis are far-reaching, not only measured by lives lost but also a considerable burden on the
criminal justice system and the economy through loss of productivity and associated healthcare
costs.
Evidence-based treatment for OUD is a multifaceted approach involving counseling and
medication-assisted treatment, specifically buprenorphine, to help patients discontinue the use of
opioids. Buprenorphine is a partial agonist on the mu-opioid receptor, therefore having less
respiratory depression and euphoria than other narcotic drugs. It is frequently combined with
naloxone to prevent intoxicating effects and has been a leading treatment for OUD since its
approval by the Food and Drug Administration (FDA) in 2002 (Drug Enforcement
Administration, 2019). Buprenorphine is relied on by the OUD community to provide a safe,
effective, and accessible means to abstinence. The role of buprenorphine is so pivotal that there
is a direct correlation between opioid overdose deaths and the lack of buprenorphine providers in
the U.S. (C. W. Jones et al., 2018). Nurse practitioners fill this void; they are more likely to serve
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underserved populations and prescribe buprenorphine at the upper end of legal limits compared
with physician (Jackson & Lopez, 2018; C. M. Jones & McCance-Katz, 2019).
Nurse practitioners were not legally permitted to prescribe buprenorphine for addiction
treatment until 2016, and as a result, they are still frequently overlooked in the fight against the
opioid epidemic. However, since the law change in 2016, nurse practitioners' roles in solving the
epidemic has rapidly grown. Despite needing to become specially certified to prescribe
buprenorphine through 24-hours of supplementary training, over 3,500 nurse practitioners, or
1.7% of those eligible, received the certification just 1 year after the law allowed (Andrilla,
2018). In 2018, only 2 years after the law passed, there were nearly 7,000 nurse practitioners
certified to treat OUD with buprenorphine (Moore, 2019). This number is likely much higher in
2021 though these data are not currently available.
Because the current evidence regarding OUD recommends treatment with long-term
buprenorphine, there is little guidance on buprenorphine cessation. Even the 24-hour
buprenorphine certification courses only teach providers the evidence-based prescribing
guidelines of buprenorphine, offering no information on discontinuing the treatment. Despite the
recommendation to prescribe buprenorphine long-term for OUD, many patients decide to
terminate buprenorphine therapy within the first 6 months of treatment (Bentzley, Barth, Back, &
Book, 2015; Fiellin et al., 2014). Although it is difficult to predict all patients’ reasoning, many
patients will taper off buprenorphine due to lack of access, (Bentzley et al., 2015; Dunn,
Saulsgiver, Miller, Nuzzo, & Sigmon, 2015) the stigma involved with medication-assisted
treatment, (Dunn et al., 2015; Truong et al., 2019) or the patients’ preferences. Since tapering
patients off buprenorphine is not an evidence-based treatment, providers do not have a
standardized treatment approach and, as a result, most patients will relapse to illicit opioid use
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within 1 month of buprenorphine cessation (Bentzley et al., 2015; Weinstein et al., 2018).
Therefore, the purpose of this paper is to review the available evidence regarding tapering
buprenorphine to aid nurse practitioners as they assist patients with the cessation process.
Methods
A search of the CINAHL, MEDLINE, and PsychInfo databases was conducted.
Inclusionary criteria included "'buprenorphine OR Suboxone' AND 'taper*.'" Different keywords
were attempted, but "taper*" was found to have the most relevant results. Limits were set to filter
results 2014 to present. Articles written in the English language were included. With these
criteria, 232 articles were found. These results were further restricted to research articles whose
main focus was tapering, and only six articles met these standards. The lack of information is
assumed to be due to the widely accepted view that buprenorphine is a long-term therapy and the
fact that buprenorphine is a relatively new treatment, with less than 20 years since FDA approval
(Drug Enforcement Administration, 2019).
As the body of literature on this topic is not large, the search was continued using a
reverse snowball strategy, or ascendancy approach. Articles that were cited frequently by key
studies were used for this paper, even if outside the established date range.
Tapering Buprenorphine Evidence
While buprenorphine is a long-term treatment therapy for OUD, many patients will
choose to terminate their buprenorphine treatment at some point. It is, therefore, the provider’s
responsibility to guide the patient through the tapering process and set proper expectations for
discontinuing buprenorphine with realistic outcomes. Since buprenorphine for OUD is used in
place of opioids, a failed taper is classified as a relapse to illicit opioid use.
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Patient Considerations
The highest predictor of a successful taper is the maintenance dose after buprenorphine
induction (Bentzley et al., 2015). There is a direct correlation between the patient’s dose and the
likelihood of relapse; with a lower dose, there is a smaller chance of relapse (Bentzley et al.,
2015; Sigmon et al., 2013). Patients with a maintenance dose of less than 8 mg of buprenorphine
per day are more likely to successfully taper off the medication. The strong association between
buprenorphine dose and successful taper is likely due to the dose being directly linked to the
level of dependence, with a higher dose indicating a higher level of dependence (Bentzley et al.,
2015). Nurse practitioners should educate patients on their likelihood of successfully
discontinuing the use of buprenorphine by weighing the probability of success against the
patient’s maintenance dose.
Additionally, the "Expected Withdrawal Scale" (EWS) is a valuable predictor of a
buprenorphine taper's withdrawal severity and helps predict patient readiness and the probability
of success (Dunn et al., 2015). With the EWS, patients rate how severe they expect withdrawal
symptoms to be on a 100-point scale. The scale is simple: on a scale of 0-100, patients give the
provider the number they feel most closely correlates with their expectation of withdrawal
symptom severity. The number 100 indicates the expectation of the worst possible withdrawal
symptoms, while the number 0 signifies no expected withdrawal symptoms. Patients' EWS score
is a great predictor of how well they will manage withdrawal symptoms; those who give lower
ratings and therefore have a better presumption of withdrawal have a better chance of a
successful taper (Dunn et al., 2015). Alternatively, patients who begin a buprenorphine taper
against their will in the inpatient setting have low success rates (Cushman, Liebschutz,
Anderson, Moreau, & Stein, 2016). Patients are considerably more likely to successfully taper
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off buprenorphine if they expect withdrawal will not be too difficult and if the choice to taper is
patient initiated (Cushman et al., 2016; Dunn et al., 2015).
Naltrexone
Naltrexone is an opioid antagonist, acting on the mu-opioid receptor. Supplementing
buprenorphine treatment with naltrexone reduces withdrawal cravings, with less likelihood of
relapse (Bentzley et al., 2015; Dunn et al., 2015; Sigmon et al., 2013). Patients with naltrexone
introduction midway through the buprenorphine taper had better success than patients who
received naltrexone after the buprenorphine was discontinued (Bentzley et al., 2015; Fiellin et
al., 2014; Sigmon et al., 2013). In fact, initiation of naltrexone after the patient had discontinued
buprenorphine was futile, as most participants had already relapsed to opioid or illicit drug use.
Additionally, when comparing treatment of extended-release naltrexone as a monotherapy
against naltrexone combined with buprenorphine, participants with the buprenorphine-naltrexone
treatment experienced fewer withdrawal symptoms and were also less likely to use opioids or
illicit drugs during the tapering process (Bisaga et al., 2018).
The inability to access a wide variety of naltrexone doses can be a limiting factor in
successful naltrexone titration, as smaller doses of naltrexone are only available at compounding
pharmacies. Due to the difficulty of access, the use of naltrexone should be addressed with
patients before the initiation of a taper from buprenorphine. Naltrexone is formulated in a 50 mg
tablet; however, many compounding pharmacies offer varying dosages as small as a 0.5 mg
capsule dose. Additionally, Vivitrol is the intramuscular formulation and is available in a vial,
which allows for incremental dosing in the clinic setting.
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Buprenorphine Taper Length with Naltrexone Initiation
Buprenorphine taper lengths vary from provider to provider, as there are no clear
guidelines that identify a best practice. The best treatment retention and lowest chance of relapse
is found with longer tapers that also initiate naltrexone (Bentzley et al., 2015; Dunn et al., 2015;
Marsch et al., 2016; Sigmon et al., 2013). A buprenorphine taper length of at least 1 month has
better results than shorter, 1- or 2-week taper lengths (Bentzley et al., 2015; Dunn et al., 2015;
Marsch et al., 2016; Sigmon et al., 2013). Even longer taper lengths that range from 30-56 days
result in milder withdrawal symptoms, with fewer moments of severe withdrawal symptoms, and
fewer sleep disruptions than with shorter buprenorphine tapers (Dunn et al., 2015).
Due to the difficulty of tapering buprenorphine and the limited evidence on the subject,
Sigmon et al.'s study offers the best guidance on the issue. Most other studies conclude a
buprenorphine taper is too risky due to the high chance of relapse and increased mortality,
especially if the patient relapses to heroin (Cushman et al., 2016; Fiellin et al., 2014; Weiss et al.,
2011). In the Sigmon et al. study, 64% of participants completed phase one's 4-week
buprenorphine taper, and 50% completed the study’s second phase with initiation of naltrexone.
Comparatively, only 3-5% of participants complete the process of tapering buprenorphine in
other studies that did not utilize naltrexone (Dunn et al., 2015; Fiellin et al., 2014). Sigmon et al.
first stabilized patients with an appropriate dose of buprenorphine, by using the Clinical Institute
Narcotic Assessment (CINA) scale to determine the amount of buprenorphine necessary to
prevent withdrawal symptoms without causing sedation (Peachey, 1988). This scale can be easily
accessed on the website https://integrationacademy.ahrq.gov/resources/7551 (Agency for
Healthcare Research and Quality). The average initiation time to become stabilized on
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buprenorphine was 8-20 days (Sigmon et al., 2013). Once the patient is stabilized on <8 mg/day
of buprenorphine, the taper has two phases (See Appendix A).
Phase One
For the first 5 weeks, the provider should slowly taper the patient’s dose of
buprenorphine. The dose is reduced by 2 mg each week until a 2 mg/day dose is reached. At that
point, the patient’s dose should decrease to a 1 mg/day dose of buprenorphine for 1 week,
followed by the patient being completely tapered off buprenorphine the following week.
Oral naltrexone is also started on week 1, at the same time as the initiation of the
buprenorphine taper, as long as the patient has one negative urine sample and self-reports no
opioid use for the last 24 hours (Dunn et al., 2015). Naltrexone begins with 12.5 mg on day one,
25 mg on days two and three, and then 50 mg daily beginning on day four and continuing for the
rest of phase one (week 1-5) (Sigmon et al., 2013). At the end of phase one, the patient is
completely tapered off buprenorphine and titrated onto a 50 mg daily dose of naltrexone.
Phase Two
Phase two includes weeks 5-12 of treatment. During this phase, the naltrexone is
transitioned to a three times per week dosing schedule with 100 mg on Mondays and
Wednesdays and 150 mg on Fridays (Sigmon et al., 2013). Upon completion of phase two,
naltrexone dosing can continue at the provider's discretion as these data were not included in this
study.
Ancillary Medication
Ancillary medications further help reduce withdrawal symptoms during the taper from
buprenorphine and are a valuable option for patients. These medications include clonidine,
trazodone, clonazepam, hydroxyzine, ibuprofen, loperamide, and promethazine. The provider

TAPERING BUPRENORPHINE

8

should prescribe medications to alleviate the withdrawal symptoms specified on the CINA or as
indicated by the patient's complaint (Bisaga et al., 2018; Dunn et al., 2015). Doses of these
ancillary medications can be administered in the office or provided as prescriptions for the
patient’s use at home (Dunn et al., 2015). While ancillary treatment should be available to
manage withdrawal symptoms, these medications should not be prescribed long-term.
Counseling
Comprehensive counseling is attributed to better treatment outcomes during
buprenorphine tapers (Sigmon et al., 2013) but can also be a reason for treatment discontinuation
if the counseling requirements are considered too strict (Bentzley et al., 2015). According to
DATA 2000, providers of buprenorphine should offer case management services and counseling
(U.S. Department of Health and Human Services, 2020). Types of counseling include
psychoeducational, cognitive-behavioral, and family systems, with mindfulness of other
concerns in the participants' life, such as legal or housing issues (Marsch et al., 2016). For best
results, counseling should be offered twice a week, with a strong suggestion of patient
participation but no requirement (Sigmon et al., 2013). Providers can educate patients to expect
better treatment outcomes with increased counseling attendance (Sigmon et al., 2013).
Schedule Requirements
Planning the tapering schedule should be meticulous and purposeful. More patients
relapse when they are required to attend the clinic daily for medication administration (Marsch et
al., 2016). In fact, patients report that daily attendance for medication administration is too
onerous and unsustainable (Marsch et al., 2016).
However, there may be circumstances when more frequent check-ins would be
necessitated. For instance, more frequent appointments may help the provider more accurately
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assess if the patient is having difficulty with the tapering course. The most withdrawal
symptoms, per patient report, is not in the beginning as most would expect, but the week
following the end of the taper (Dunn et al., 2015). Knowing that patients continue to struggle
beyond the length of the taper course would be helpful when scheduling, counseling, and
preparing patients for their taper. There are better outcomes for patients between the ages of 16
and 24 when patients received buprenorphine daily in the clinic instead of self-administration of
buprenorphine at home (Marsch et al., 2016).
Implications for Clinical Practice
Evidence is clear that buprenorphine is best used as a long-term medication for OUD.
However, there are several reasons that a patient may need or desire to be tapered off of the drug.
In the case that a buprenorphine taper is warranted, the nurse practitioner can follow the
buprenorphine taper algorithm noted in Appendix A.
Recommendations
Tapering buprenorphine should begin with a discussion about the process and challenges
involved in buprenorphine cessation. Eligibility and future success are predicted based on the
stable dose of buprenorphine (<8 mg/day) and a low EWS . Once the taper is initiated, the nurse
practitioner may also prescribe ancillary medications to assist with withdrawal symptoms during
the taper, keeping in mind that the withdrawal symptoms usually peak during week 5.
Counseling services should also be offered as adjunct to the taper protocol. The nurse
practitioner should decide with the patient how frequently the patient will follow-up in clinic.
Following these recommendations gives patients the best opportunity for a successful taper from
buprenorphine.
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Limitations
The data on tapering buprenorphine is limited. Only a few clinical trials focused on
tapering buprenorphine. Most studies on buprenorphine cessation had high attrition rates. In fact,
in some research studies nearly every participant in the taper group prematurely dropped out of
the study (Fiellin et al., 2014). Many of the studies with the lowest rates of completion had the
shortest buprenorphine taper periods, with some as short as 1-2 weeks (Dunn et al., 2015; Fiellin
et al., 2014; Sigmon et al., 2013; Weiss et al., 2011). This finding indicates that tapering off of
buprenorphine remains a significant clinical challenge. Due to the small number of available
clinical trials regarding buprenorphine cessation, more high-quality research is needed in this
area There is also a need for additional research with tapering buprenorphine across diverse
patient demographics.
Conclusion
OUD is a rising problem, affecting many patients. Nurse practitioners need to prepare to
care for patients with OUD, which includes prescribing buprenorphine. Although the gold
standard of buprenorphine therapy is long-term treatment, many patients may choose to taper off
buprenorphine. Information regarding successful buprenorphine tapering is limited; therefore,
there is a need for more research in this area. The nurse practitioner should inform the patient
seeking discontinuance of buprenorphine of the lack of evidence in how to successfully taper
buprenorphine. If the patient wishes to continue, the nurse practitioner should determine the
patient's likelihood of success by evaluating the patient's buprenorphine stabilization dose and
their expectations of withdrawal severity. If buprenorphine cessation is still the patient's goal, the
nurse practitioner should start the patient on a two-phase taper schedule with simultaneous
naltrexone initiation. The nurse practitioner can and should prescribe ancillary medications as
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indicated by CINA scores and can adjust counseling and schedule requirements on a per-patient
basis. Tapering off buprenorphine is challenging but having a nurse practitioner who is equipped
with the best available evidence is an invaluable tool to give patients the best possibility of
success.
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